Valuation : Rapport Therapeutics, Inc.

Market Cap 2.34B 2.01B 1.89B 1.72B 3.24B 222B 3.26B 22.37B 8.7B 113B 8.77B 8.58B 373B P/E 2026 *
-12x
P/E 2027 * -9.93x
Enterprise Value 2.01B 1.73B 1.62B 1.48B 2.78B 191B 2.8B 19.22B 7.48B 96.79B 7.53B 7.37B 320B EV / Sales 2026 *
100x
EV / Sales 2027 * -
Free-Float
96.08%
Yield 2026 *
-
Yield 2027 * -
1 day-0.21%
1 week-1.34%
Current month+18.77%
1 month+18.77%
3 months+31.15%
6 months+74.76%
Current year+60.42%
1 week 47.51
Extreme 47.51
52.93
1 month 39.75
Extreme 39.75
52.93
Current year 25.21
Extreme 25.21
52.93
1 year 14.11
Extreme 14.11
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 2022-12-31
Chief Executive Officer 48 2023-01-31
Director of Finance/CFO 58 2023-10-31
Director TitleAgeSince
Director/Board Member 61 2023-08-22
Director/Board Member 48 2023-02-28
Director/Board Member 54 2022-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/25/26 Sell

Executive/Senior Manager

-37,000 0.0774%
8/25/26 Sell

Chief Executive Officer

-18,921 0.0396%
8/19/26 Sell

Executive/Senior Manager

-404 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-1.34%+197.31% - 2.34B
-1.23%-1.91%+0.98%+17.94% 50.47B
-1.11%-2.84%+420.04%+505.15% 44.56B
-0.21%+0.37%+36.88%+17.32% 43.08B
-1.95%-3.33%+8.29%+73.25% 41.7B
-0.94%-1.77%+18.34%+46.84% 33.21B
-1.11%-4.20%+25.49%+119.78% 16.77B
+6.10%+4.40% - - 16.28B
+0.25%-0.98%+11.91%+27.62% 14.58B
-1.12%-3.46%+76.50%+39.37% 13.92B
Average -0.15%-1.75%+88.42%+105.91% 27.69B
Weighted average by Cap. -0.60%-1.57%+89.93%+122.85%

Financials

2026 *2027 *
Net sales 20M 17.22M 16.17M 14.76M 27.73M 1.9B 27.93M 192M 74.55M 965M 75.09M 73.46M 3.2B -
Net income -194M -167M -157M -143M -269M -18.47B -271M -1.86B -724M -9.37B -729M -713M -31.01B -252M -217M -204M -186M -350M -24.02B -352M -2.42B -941M -12.18B -948M -927M -40.32B
Net Debt -329M -283M -266M -243M -456M -31.31B -460M -3.15B -1.23B -15.88B -1.24B -1.21B -52.58B -477M -410M -385M -352M -661M -45.36B -666M -4.57B -1.78B -23B -1.79B -1.75B -76.16B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
26-08-31 US$48.67 -0.21% 221,024
26-08-28 US$48.77 -4.05% 332,731
26-08-27 US$50.83 -3.18% 382,834
26-08-26 US$52.50 +2.60% 275,271
26-08-25 US$51.17 +3.73% 324,500
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
48.67USD
Average target price
62.05USD
Spread / Average Target
+27.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock